MTOR signaling and human cancer

Enzymes

Volumn 28, Issue C, 2010, Pages 301-316

  Chantaravisoot, Naphat ^a   Tamanoi, Fuyuhiko ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIA;

EID: 77957232925     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1874-6047(10)28015-0     Document Type: Book

References (51)

1. Abraham R.T. PI 3-indase related kinases: 'big' players in stress-induced signaling pathways. DNA Repair (Amst) 2004, 3:883-887.
2. Polak P., Hall M.N. mTOR and the control of whole body metabolism. Curr Opin Cell Biol 2009, 21:209-218.
3. Laplante M., Sabatini D.M. mTOR signaling at a glance. J Cell Sci 2009, 122:3589-3594.
4. Memmott R.M., Dennis P.A. Akt-dependent and independent mechanisms of mTOR regulation in cancer. Cell Signal 2009, 21:656-664.
5. T. Sato, A. Nakashima, L. Guo, K. Coffman, F. Tamanoi, Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer, Oncogene 29 2746-2752.
6. Stratton M.R., Campbell P.J., Futreal P.A. The cancer genome. Nature 2009, 458:719-724.
7. Johnson B.E., Jackman D., Janne P.A. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res 2007, 13:s468-s4631.
8. Wang X., Yue P., Kim Y.A., Fu H., Khuri F.R., Sun S.Y. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008, 68:7409-7418.
9. S.V. Bhagwat, A.P. Crew, Novel inhibitors of mTORC1 and mTORC2, Curr Opin Investig Drugs 11 638-645.
10. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
11. Lu K.H., et al. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res 2009, 14:2543-2550.
12. Karbowiniczek M., Spittle C.S., Morrison T., Wu H., Hesnke E.P. mTOR is activated in the majority of malignant malanomas. J Invest Dermatol 2008, 128:980-987.
13. Nozawa H., Watanabe T., Nagawa H. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett 2007, 251:105-113.
14. Baba H.A., et al. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int 2009, 29:399-405.
15. Molinolo A.A., et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissues array initiative. Clin Cancer Res 2007, 13:4964-4973.
16. Robb V.A., Karbowniczek M., Klein-Szanto A.J., Henske E.P. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007, 177:346-352.
17. Pantuck A.J., et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007, 109:2257-2267.
18. Lang S.A., et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007, 120:1803-1810.
19. Annovazzi L., Mellai M., Caldera V., Valente G., Tessitore L., Schiffer D. mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma. Anticancer Res 2009, 29:3087-3094.
20. Chen S., et al. Immunohistochemical analysis of the mammalian target of rapamycin signaling pathway in extramammary Paget's disease. Br J Dermatol 2009, 161:357-363.
21. Follo M.Y., et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 2007, 67:4287-4294.
22. Inoki K., Corradetti M.N., Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005, 37:19-24.
23. Kwiatkowski D.J., Manning B.D. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 2005, 14(Spec No. 2):R251-R258.
24. Gau C.L., Kato-Stankiewicz J., Jiang C., Miyamoto S., Guo L., Tamanoi F. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Mol Cancer Ther 2005, 4:918-926.
25. Uhlmann E.J., Li W., Scheidenhelm D.K., Gau C.L., Tamanoi F., Gutmann D.H. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia 2004, 47:180-188.
26. Kenerson H., Folpe A.L., Takayama T.K., Yeung R.S. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol 2007, 38:1361-1371.
27. Robb V.A., Astrinidis A., Henske E.P. Frequent hyperphosphorylation of ribosomal protein S6 in lymphangioleiomyomatosis-associated angiomyolipomas. Mod Pathol 2006, 19:839-846.
28. Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 2007, 26:7825-7832.
29. Sancak Y., et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007, 25:903-915.
30. Peterson T.R., et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137:873-886.
31. Kiaris H., Spandidos D.A. Mutations of ras genes in human tumours. Int J Oncol 1995, 7:413-421.
32. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
33. Aspuria P.J., Sato T., Tamanoi F. The TSC/Rheb/TOR signaling pathway in fission yeast and mammalian cells: temperature sensitive and constitutive active mutants of TOR. Cell Cycle 2007, 6:1692-1695.
34. Matsuo T., Otsubo Y., Urano J., Tamanoi F., Yamamoto M. Loss of the TOR kinase Tor2 mimics nitrogen starvation and activates the sexual development pathway in fission yeast. Mol Cell Biol 2007, 27:3154-3164.
35. Urano J., Sato T., Matsuo T., Otsubo Y., Yamamoto M., Tamanoi F. Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc Natl Acad Sci USA 2007, 104:3514-3519.
36. Sehgal S.N., Baker H., Vezina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975, 28:727-732.
37. Shor B., Gibbons J.J., Abraham R.T., Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009, 8:3831-3837.
38. Thoreen C.C., Sabatini D.M. Rapamycin inhibits mTORC1, but not completely. Autophagy 2009, 5:725-726.
39. Apsel B., et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 2009, 4:691-699.
40. Feldman M.E., et al. Active-site inhibitors of mTOR target of rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009, 7:e38.
41. Bhagwat S.V., et al. OSI-027 a potent and selective small molecule mTORC11/mTORC2 kinase inhibitor is mechanistically distinct from rapamycin 2010, AACR Annual Meeting 2010, Abstract nr 4487.
42. Yu K., et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009, 69:6232-6240.
43. K. Yu, et al., Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2, Cancer Res 70 621-631.
44. Garcia-Martinez J.M., et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 2009, 421:29-42.
45. C.M. Chresta, et al., AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity, Cancer Res 70 288-298.
46. Thoreen C.C., et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009, 284:8023-8032.
47. Kessler L., et al. INK128, an orally active TOC1/2 kinase inhibitor, shows broad antitumor activity and enhances efficacy of cytotoxic as well as targeted agents 2010, ACCR Annual Meeting 2010, Abstract nr 4496.
48. Gross S.D., et al. AR-mTOR-26- A potent, selective mTORC1/2 kinase inhibitor for the treatment of malignancy 2010, AACR Annual Meeting 2010, Abstract nr 4484.
49. Janes M.R., et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010, 16:205-213.
50. Gokhale P.C., et al. OSI-027 a selective dual mTORC1/TORC2 kinase inhibitor displays broad spectrum anti-tumor activity in preclinical models of human cancer 2010, AACR Annual Meeting 2010, Abstract nr 4486.
51. Wang S., et al. INK128: an orally active TORC1/2 kinase inhibitor demonstrates potent antitumor activity in preclinical models of renal cell carcinoma 2010, AACR Annual Meeting 2010, Abstract nr 4488.